AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance
Authors:
Open Access
- 1 August 2026
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 49 (12) , 1579-1594
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline Biologicals
This publication has 53 references indexed in Scilit:
- RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 SeasonsJAMA, 2025
- Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or OlderJAMA Network Open, 2025
- Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract DiseaseJAMA Network Open, 2024
- Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65Infectious Diseases and Therapy, 2024
- RSV vaccine and nirsevimab administration errorsReactions Weekly, 2024
- Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT–PCRInfectious Diseases and Therapy, 2023
- Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling StudyInfectious Diseases and Therapy, 2023
- Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018JAMA Network Open, 2020
- Pharmacoepidemiological considerations in observed‐to‐expected analyses for vaccinesPharmacoepidemiology and Drug Safety, 2015
- Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized ProblemDrugs & Aging, 2015